Filtered By:
Specialty: Cardiology
Condition: Cardiomyopathy

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 533 results found since Jan 2013.

Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction
Abstract Hypertrophic cardiomyopathy (HCM) with systolic dysfunction carries a poor prognosis. Although late gadolinium enhancement (LGE) on cardiac magnetic resonance is associated with adverse cardiac events in HCM and is inversely related to left ventricular ejection fraction (LVEF), it is unknown whether LGE or LVEF more accurately predicts adverse cardiac events in HCM with systolic dysfunction. We retrospectively assessed the extent of LGE with a threshold of 6 standard deviations in 46 consecutive HCM patients with systolic dysfunction defined as LVEF <50 % (average 35 ± 12 %) who underwent cardiac ...
Source: Heart and Vessels - March 28, 2015 Category: Cardiology Source Type: research

Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial
This study is registered at clinicaltrials.gov-NCT00417222.
Source: European Heart Journal - April 14, 2015 Category: Cardiology Authors: Sakata, Y., Shiba, N., Takahashi, J., Miyata, S., Nochioka, K., Miura, M., Takada, T., Saga, C., Shinozaki, T., Sugi, M., Nakagawa, M., Sekiguchi, N., Komaru, T., Kato, A., Fukuchi, M., Nozaki, E., Hiramoto, T., Inoue, K., Goto, T., Ohe, M., Tamaki, K., I Tags: Heart failure/cardiomyopathy Source Type: research

Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
CONCLUSIONS: MAPSE measurement using CMR is feasible, reproducible and comparable to echocardiography in healthy controls and patients with HCM. The asymmetric and mainly septal distribution of myocardial hypertrophy and fibrosis detected by LGE in patients with HCM was reflected by significantly reduced septal versus lateral MAPSE. Therefore, reduced MAPSE seems to be an easily determinable marker of fibrosis accumulation leading to left ventricular mechanical dysfunction and also seems to have a prognostic implication. PMID: 25863428 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - April 8, 2015 Category: Cardiology Authors: Doesch C, Sperb A, Sudarski S, Lossnitzer D, Rudic B, Tülümen E, Heggemann F, Schimpf R, Schoenberg SO, Borggrefe M, Papavassiliu T Tags: Arch Cardiovasc Dis Source Type: research

Massive Left Ventricular Calcification
94-year-old male presented for follow-up for shortness of breath. He has a history of two episodes of anterior and inferior myocardial infarction (MI) (eight and thirteen years ago) with stent revascularization, ischemic cardiomyopathy, implantable cardioverter defibrillator, paroxysmal atrial fibrillation, hypertension, hyperlipidemia, diabetes, and stroke. Lab investigation showed normal kidney function and calcium level. Echocardiography showed a reduced left ventricular (LV) ejection fraction of 25%, diastolic dysfunction, severe anteroseptal hypokinesis, otherwise normal LV.
Source: International Journal of Cardiology - April 28, 2015 Category: Cardiology Authors: Anas Alani Tags: Letter to the Editor Source Type: research

Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies
ConclusionsIn a large longitudinally assessed adult HCM cohort, we have demonstrated that contemporary management strategies and treatment interventions, including ICDs for SD prevention, have significantly altered the clinical course, now resulting in a low disease-related mortality rate of 0.5%/year and an opportunity for extended longevity.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - May 4, 2015 Category: Cardiology Source Type: research

Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women
In this study, we sought to identify the risk and risk factors for adverse maternal and fetal events in pregnant women with underlying heart disease. Pregnant women referred for echocardiogram with known or suspected heart disease were categorized into those with: (1) cardiomyopathy, (2) other heart disease (HD; congenital, coronary, arrhythmia, or valvular), and (3) no HD. Primary outcome was major adverse cardiovascular events (MACE), defined as a composite of death, sustained arrhythmia, myocardial infarction, heart failure, and transient ischemic attack/stroke.
Source: The American Journal of Cardiology - May 8, 2015 Category: Cardiology Authors: Paraskevi Koutrolou-Sotiropoulou, Puja B. Parikh, Charles Miller, Fabio Vasconcelos Lima, Javed Butler, Kathleen Stergiopoulos Source Type: research

Effect of a myosin regulatory light chain mutation K104E on actin-myosin interactions
Familial hypertrophic cardiomyopathy (FHC) is the most common cause of sudden cardiac death in young individuals. Molecular mechanisms underlying this disorder are largely unknown; this study aims at revealing how disruptions in actin-myosin interactions can play a role in this disorder. Cross-bridge (XB) kinetics and the degree of order were examined in contracting myofibrils from the ex vivo left ventricles of transgenic (Tg) mice expressing FHC regulatory light chain (RLC) mutation K104E. Because the degree of order and the kinetics are best studied when an individual XB makes a significant contribution to the overall s...
Source: AJP: Heart and Circulatory Physiology - May 15, 2015 Category: Cardiology Authors: Duggal, D., Nagwekar, J., Rich, R., Huang, W., Midde, K., Fudala, R., Das, H., Gryczynski, I., Szczesna-Cordary, D., Borejdo, J. Tags: MUSCLE MECHANICS AND VENTRICULAR FUNCTION Source Type: research

Pacing for treatment and prevention of atrial fibrillation: Is there an end to this story?Editorial Commentary
Pacemakers are frequently implanted in patients with atrial fibrillation (AF), which is the most common sustained cardiac arrhythmia with causal association with stroke, heart failure, cardiomyopathy, and all-cause mortality.1–5 In a general pacemaker population, AF can also develop frequently and progressively over time.6 Thus, as no surprise, the story of “pacing and AF” has been going around for a long time.1–7 The article by Padeletti et al8 in this issue of HeartRhythm perhaps adds a new twist.
Source: Heart Rhythm - May 5, 2015 Category: Cardiology Authors: Bharat K. Kantharia Tags: Editorial Commentary Source Type: research

Clinical Characteristics and Long-Term Outcomes of Hypertrophic Cardiomyopathy.
Authors: Yoshinaga M, Yoshikawa D, Ishii H, Hirashiki A, Okumura T, Kubota A, Sakai S, Harada K, Somura F, Mizuno T, Fujiwara W, Yokoi H, Hayashi M, Ishii J, Murohara T, Yoshida Y, Amano T, Izawa H Abstract Hypertrophic cardiomyopathy (HCM) has various morphological and clinical features. A decade has passed since the previous survey of the epidemiological and clinical characteristics of Japanese HCM patients. The Aichi Hypertrophic Cardiomyopathy (AHC) Registry is based on a prospective multicenter observational study of HCM patients. The clinical characteristics of 42 ambulant HCM patients followed up for up to 5...
Source: International Heart Journal - June 19, 2015 Category: Cardiology Tags: Int Heart J Source Type: research

Standing on the Shoulders of Giants: JAP Paré and the Birth of Cardiovascular Genetics
Publication date: Available online 17 June 2015 Source:Canadian Journal of Cardiology Author(s): Srijita Sen-Chowdhry , William J. McKenna Sudden death and stroke afflicted a family from rural Quebec with such frequency as to be called the Coaticook curse by the local community. In Montreal in the late 1950s, a team of physicians led by JAP Paré investigated this family for inherited cardiovascular disease. Their efforts resulted in an extensive and now classic description of familial hypertrophic cardiomyopathy. A quarter of a century later, the same family was the subject of linkage analysis and direct sequencing, cul...
Source: Canadian Journal of Cardiology - June 22, 2015 Category: Cardiology Source Type: research

Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?
Abstract Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac conditions. Atrial fibrillation (AF) has been demonstrated to be the most frequent arrhythmia encountered in HCM patients. Research focusing on AF and embolic stroke in HCM patients has been sparse and the sample size of most studies is small. The prognostic significance of AF in HCM patients is still not well known. The aim of this article is to provide further understanding of the anti-coagulation requirement of HCM patients with AF.
Source: Clinical Research in Cardiology - July 2, 2015 Category: Cardiology Source Type: research

Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)
Conclusion Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure. Study registration number NCT00644410 (ClinicalTrials.gov).
Source: European Heart Journal - July 14, 2015 Category: Cardiology Authors: Mathiasen, A. B., Qayyum, A. A., Jorgensen, E., Helqvist, S., Fischer-Nielsen, A., Kofoed, K. F., Haack-Sorensen, M., Ekblond, A., Kastrup, J. Tags: Interventional cardiology Source Type: research

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Conclusions LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration https://clinicaltrials.gov/, NCT01035255.
Source: European Heart Journal - August 7, 2015 Category: Cardiology Authors: Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., Solomon, S. D. Tags: Heart failure/cardiomyopathy Source Type: research

Dabigatran for left ventricular thrombus
Publication date: Available online 8 August 2015 Source:Indian Heart Journal Author(s): Satishkumar Kolekar, Chandrashekhar Munjewar, Satyavan Sharma Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued due to marked fluctuations in INR. Transthoracic Echocardiography (TTE) revealed a mobile mass in the left ventricle. He...
Source: Indian Heart Journal - August 8, 2015 Category: Cardiology Source Type: research

Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
Conclusions The blinded placebo-controlled STOP-HF trial demonstrated the safety of a single endocardial administration of pSDF-1 but failed to demonstrate its primary endpoint of improved composite score at 4 months after treatment. Through a pre-specified analysis the STOP-HF trial demonstrates the potential for attenuating LV remodelling and improving EF in high-risk ischaemic cardiomyopathy. The safety profile supports repeat dosing with pSDF-1 and the degree of left ventricular remodelling suggests the potential for improved outcomes in larger future trials.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Chung, E. S., Miller, L., Patel, A. N., Anderson, R. D., Mendelsohn, F. O., Traverse, J., Silver, K. H., Shin, J., Ewald, G., Farr, M. J., Anwaruddin, S., Plat, F., Fisher, S. J., AuWerter, A. T., Pastore, J. M., Aras, R., Penn, M. S. Tags: Heart failure/cardiomyopathy Source Type: research